ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VRCA vs RFL // GROSS PROFIT MARGIN

Verrica Pharmaceuticals Inc. (NASDAQ) VS. Rafael Holdings Inc. (Class B) (NYSE) • 15-METRIC TALLY: VRCA 6 — RFL 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRCA VS. RFL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VRCA RFL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -34.20% -60.00% +25.80 VRCA /operating-margins <GO>
Net Profit Margin -50.30% -60.00% +9.70 VRCA /net-margins <GO>
Revenue Growth (YoY) 180.00% -65.00% +245.00 VRCA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 VRCA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.1 31.0 +3.10 VRCA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $58.8M $58.2M $511.5K VRCA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VRCA REV RFL REV VRCA GROSS % RFL GROSS % VRCA FCF RFL FCF
FY 2025 $35.6M $30.0K — — -$17.6M -$18.9M
FY 2024 $7.6M $637.0K 65.6% 75.8% -$61.0M -$7.9M
FY 2023 $5.1M $279.0K — — -$38.6M -$10.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRCA // BETA —
RFL // BETA —